How to Increase Your Semaglutide Dose Safely

Step 1: Understand the licensed UK dose ladder before requesting an increase

Wegovy's titration schedule is set by the medicine's UK licence, not by personal preference or how quickly weight loss is progressing. The five steps are 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg, each intended to last at least four weeks. The full Wegovy dose schedule is designed this way because the gut needs time to adapt to each new concentration of semaglutide. Rushing the ladder is one of the most common reasons people experience severe nausea or have to pause treatment entirely.

The 0.25 mg starting dose isn't doing much therapeutically, its job is simply to reduce the chance of significant GI upset when the body first encounters the medicine. Appetite suppression and the clinical effect on weight build gradually as the dose rises. The NHS semaglutide medicines page confirms this titration sequence and explains what to expect at each stage. Worth reading before your next review.

A wider overview of how Wegovy works may also help frame why the process is gradual rather than immediate.

Step 2: Know what to have ready when asking your prescriber about moving up

Your prescriber needs a clear picture before approving a semaglutide dose increase. That typically means: how long you've been on the current dose, how well you've tolerated it (specifically, any nausea, vomiting, or reflux), what weight change has occurred, and whether anything else in your health picture has changed since treatment began.

At nume, every repeat order and dose-increase request is read by a real prescriber, not processed automatically. Evidence of your current dose and how you've been getting on is part of that review. If you use a multidose pen, keeping a brief note in your phone of any side effects after each injection takes thirty seconds and makes that conversation far more productive.

The question of when exactly to move to the next semaglutide dose has a more detailed answer than most people expect, individual factors, not just calendar weeks, shape the timing. Read that page before contacting your prescriber if you're unsure.

Storage matters here too: Wegovy pens should be kept in the fridge (2–8°C), and a quick check that your current pen hasn't been left out beyond its room-temperature limit before you contact your prescriber means no confusion about whether a dose was correctly taken.

Step 3: What happens at the dose increase, and how to manage the transition

Once a prescriber approves the next step, the increase takes effect from your very next injection at the new strength. There's no partial ramp, you move fully to the new dose. This is why the titration steps exist: each jump is calibrated to be manageable rather than dramatic.

The side effects that tend to appear after a semaglutide dose increase are mostly gastrointestinal, nausea is the most reported, followed by looser stools, bloating, or reduced appetite extending to the point of not wanting to eat much at all. These are usually most noticeable in the 24–48 hours after injection and ease across the following week or two. Staying well hydrated and eating smaller, lower-fat meals during that settling period makes a measurable difference for most people.

NICE's appraisal of semaglutide for weight management, TA875, notes that treatment should be reviewed if less than 5% weight loss has occurred after six months at the maintenance dose, context worth keeping in mind when thinking about whether the increase is working.

If side effects at the new dose are genuinely difficult to manage, speak to your prescriber before the next scheduled injection. Staying at the previous dose for another four weeks, rather than stopping treatment, is often the more sensible clinical route. See more detail on the process of increasing your semaglutide dose if you want to explore those options.

When 2.4 mg isn't the end: the 7.2 mg dose

For patients who reach the 2.4 mg maintenance dose but feel there's further to go, there is now a licensed higher option. The MHRA approved a 7.2 mg maintenance dose for Wegovy in January 2026, with a dedicated single-dose pen approved in April 2026 for adults with a BMI of 30 or above. Titration still begins at 0.25 mg (you don't start at 7.2 mg) and the route to this dose runs through the same four-weekly steps.

Trial data reported approximately 20.7% average weight loss over 72 weeks at the 7.2 mg dose, bringing results closer to those seen with tirzepatide at its highest strength. The Wegovy 7.2 mg dose is a meaningful development, but it's not appropriate for everyone, BMI, current tolerance and overall health picture all factor in. Whether this is a route worth exploring is a conversation for your prescriber, not a decision to make based on the number alone.

If you're thinking about starting Wegovy or want a clinical review of where you are in your titration, the free consultation at nume connects you with a GPhC-registered prescriber the same day.